Explore

Waiv Collaborates with Daiichi Sankyo to Advance AI-Derived Biomarkers for ADC Program

Waiv Collaborates with Daiichi Sankyo to Advance AI-Derived Biomarkers for ADC Program

Waiv Collaborates with Daiichi Sankyo to Advance AI-Derived Biomarkers for ADC Program

Cytospire Secures $83 Million for Innovative T-Cell Engager Platform

Cytospire Secures $83 Million for Innovative T-Cell Engager Platform

Cytospire Secures $83 Million for Innovative T-Cell Engager Platform

Merck Completes Acquisition of Terns Pharmaceuticals, Expanding Oncology Pipeline

Merck Completes Acquisition of Terns Pharmaceuticals, Expanding Oncology Pipeline

Merck Completes Acquisition of Terns Pharmaceuticals, Expanding Oncology Pipeline

Sensei Biotherapeutics Begins Phase 1b/2 Trial of PIKTOR for Advanced Breast Cancer

Sensei Biotherapeutics Begins Phase 1b/2 Trial of PIKTOR for Advanced Breast Cancer

Sensei Biotherapeutics Begins Phase 1b/2 Trial of PIKTOR for Advanced Breast Cancer

Personalized Medicine Market Projected to Reach USD 1,397.63 Billion by 2035 Due to Genomic Advancements

Personalized Medicine Market Projected to Reach USD 1,397.63 Billion by 2035 Due to Genomic Advancements

Personalized Medicine Market Projected to Reach USD 1,397.63 Billion by 2035 Due to Genomic Advancements

How Peptides Aim at Disease With Unusual Precision

How Peptides Aim at Disease With Unusual Precision

Peptides have emerged as a significant class of compounds in the field of medicine, offering promising therapeutic potential. These short chains of...

Nuvectis Pharma Reports Increased Net Loss in Q1 2026

Nuvectis Pharma Reports Increased Net Loss in Q1 2026

Nuvectis Pharma Reports Increased Net Loss in Q1 2026

Allarity Therapeutics Advances Stenoparib Toward Phase 3 Development for Ovarian Cancer

Allarity Therapeutics Advances Stenoparib Toward Phase 3 Development for Ovarian Cancer

Allarity Therapeutics Advances Stenoparib Toward Phase 3 Development for Ovarian Cancer

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

ADC Therapeutics Reports Q1 2026 Financial Results and Operational Updates

Pharmaceutical Leaders Utilize Protein Biomarkers to Mitigate Drug Development Risks

Pharmaceutical Leaders Utilize Protein Biomarkers to Mitigate Drug Development Risks

Pharmaceutical Leaders Utilize Protein Biomarkers to Mitigate Drug Development Risks

Allarity Therapeutics Advances Stenoparib Manufacturing for Phase 3 Trials in Ovarian Cancer

Allarity Therapeutics Advances Stenoparib Manufacturing for Phase 3 Trials in Ovarian Cancer

Allarity Therapeutics Advances Stenoparib Manufacturing for Phase 3 Trials in Ovarian Cancer

IDEAYA Biosciences Reports Positive Trial Results and Financial Update for Q1 2026

IDEAYA Biosciences Reports Positive Trial Results and Financial Update for Q1 2026

IDEAYA Biosciences Reports Positive Trial Results and Financial Update for Q1 2026